2024
Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study
Jain S, Anderson S, Steele J, Wilson H, Muniz J, Soslow J, Beroukhim R, Maksymiuk V, Jacquemyn X, Frosch O, Fonseca B, Harahsheh A, Buddhe S, Ashwath R, Thacker D, Maskatia S, Misra N, Su J, Siddiqui S, Vaiyani D, Vaikom-House A, Campbell M, Klein J, Huang S, Mathis C, Cornicelli M, Sharma M, Nagaraju L, Ang J, Uppu S, Ramachandran P, Patel J, Han F, Mandell J, Akam-Venkata J, DiLorenzo M, Brumund M, Bhatla P, Eshtehardi P, Mehta K, Glover K, Dove M, Aldawsari K, Kumar A, Barfuss S, Dorfman A, Minocha P, Yonts A, Schauer J, Cheng A, Robinson J, Powell Z, Srivastava S, Chelliah A, Sanil Y, Hernandez L, Gaur L, Antonchak M, Johnston M, Reich J, Nair N, Drugge E, Grosse-Wortmann L. Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study. EClinicalMedicine 2024, 76: 102809. PMID: 39290640, PMCID: PMC11406334, DOI: 10.1016/j.eclinm.2024.102809.Peer-Reviewed Original ResearchCOVID-19 vaccine-associated myocarditisLate gadolinium enhancementMid-term clinical outcomesVaccine-associated myocarditisCardiac magnetic resonanceMyocardial injuryMulticenter studyClinical diagnosis of acute myocarditisThird dose of mRNA vaccineDiagnosis of acute myocarditisDose of mRNA vaccinePresence of myocardial injuryNo cardiac deathsMedian follow-upCohort multicenter studyMultisystem inflammatory syndromeFollow-up informationCardiac manifestationsAcute myocarditisClinical courseInflammatory syndromeClinical presentationGadolinium enhancementCardiac dysfunctionThird doseA fiery heart: case report of perimyocarditis in a patient with eosinophilic granulomatosis with polyangiitis
Park D, Planek M, Mohammed A, Nanna M, Alyousef T. A fiery heart: case report of perimyocarditis in a patient with eosinophilic granulomatosis with polyangiitis. European Heart Journal - Case Reports 2024, 8: ytae414. PMID: 39420958, PMCID: PMC11483628, DOI: 10.1093/ehjcr/ytae414.Peer-Reviewed Original ResearchLate gadolinium enhancementEosinophilic granulomatosisCase reportFrequent non-sustained ventricular tachycardiaInterstitial infiltrates of eosinophilsSubendocardial late gadolinium enhancementSubepicardial late gadolinium enhancementElevated immunoglobulin E levelsNon-sustained ventricular tachycardiaGuideline-directed medical therapyCardiac magnetic resonance imagingAssociated with high morbidityCase of EGPATreated with prednisoneDilated cardiac chambersManifestation of EGPAImmunoglobulin E levelsMedium-sized vessel vasculitisSharp chest painYoung female patientLeft upper lobeGround-glass opacitiesDiverse clinical manifestationsInfiltration of eosinophilsMagnetic resonance imagingCardiac magnetic resonance for ventricular arrhythmias: a systematic review and meta-analysis
Papanastasiou C, Bazmpani M, Kampaktsis P, Zegkos T, Gossios T, Parcharidou D, Kokkinidis D, Tziatzios I, Economou F, Nikolaidou C, Kamperidis V, Tsapas A, Ziakas A, Efthimiadis G, Karamitsos T. Cardiac magnetic resonance for ventricular arrhythmias: a systematic review and meta-analysis. Heart 2024, 110: 1113-1123. PMID: 39084706, DOI: 10.1136/heartjnl-2024-324182.Peer-Reviewed Original ResearchPrevalence of structural heart diseaseCardiac magnetic resonanceStructural heart diseaseVentricular arrhythmiasPrognostic value of cardiac magnetic resonancePresence of late gadolinium enhancementPrognostic evaluation of patientsHeart diseaseNon-ischaemic cardiomyopathyAssociated with increased riskRandom-effects model meta-analysisLate gadolinium enhancementMeta-analysisEvaluation of patientsImprove risk stratificationMyocardial tissue characterisationIschaemic heart diseaseGadolinium enhancementPrognostic implicationsMyocardial inflammationPrognostic valueAdult patientsHypertrophic cardiomyopathyPooled ratePrognostic evaluationElevated myocardial extracellular volume fraction is associated with the development of conduction pathway defects following transcatheter aortic valve replacement
Feroze R, Kang P, Dallan L, Akula N, Galo J, Yoon S, Ukaigwe A, Filby S, Baeza C, Pelletier M, Rushing G, Rajagopalan S, Al‐Kindi S, Rashid I, Attizzani G. Elevated myocardial extracellular volume fraction is associated with the development of conduction pathway defects following transcatheter aortic valve replacement. Catheterization And Cardiovascular Interventions 2024, 104: 1119-1128. PMID: 38952304, DOI: 10.1002/ccd.31136.Peer-Reviewed Original ResearchMeSH KeywordsAction PotentialsAgedAged, 80 and overAortic ValveAortic Valve StenosisArea Under CurveAtrioventricular BlockBundle-Branch BlockCardiac Pacing, ArtificialFemaleFibrosisHeart Conduction SystemHumansMagnetic Resonance Imaging, CineMaleMyocardiumPacemaker, ArtificialPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsROC CurveTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementCardiac magnetic resonance imagingLate gadolinium enhancementRight bundle branch blockArea under the receiver operating characteristic curveAortic valve replacementReceiver operating curveMyocardial fibrosisPost-TAVRConduction defectsBundle branch blockAssociations of myocardial fibrosisExtracellular volumeConduction diseaseValve replacementGadolinium enhancementPermanent pacemakerConduction abnormalitiesConduction deficitsHeart blockBranch blockRisk of heart blockSeptal late gadolinium enhancementMyocardial extracellular volume fractionBaseline conduction disease
2023
Atrial fibrosis by cardiac MRI is a correlate for atrial stiffness in patients with atrial fibrillation
Lamy J, Taoutel R, Chamoun R, Akar J, Niederer S, Mojibian H, Huber S, Baldassarre L, Meadows J, Peters D. Atrial fibrosis by cardiac MRI is a correlate for atrial stiffness in patients with atrial fibrillation. The International Journal Of Cardiovascular Imaging 2023, 40: 107-117. PMID: 37857929, PMCID: PMC11378145, DOI: 10.1007/s10554-023-02968-x.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementLA reservoir strainLeft atrial pressureLA volumeReservoir strainLA fibrosisLA strainStiffness indexLA late gadolinium enhancementAtrial stiffness indexMaximal LA volumeAtrial fibrillation cohortLA minimum volumeAtrial tissue fibrosisMaximum LA volumeCardiac MR examsAtrial stiffnessAtrial strainAF ablationAtrial pressureAF cohortAtrial fibrillationAtrial fibrosisPatient subgroupsLGE volumeImaging Acute and Chronic Cardiac Complications of COVID-19 and after COVID-19 Vaccination.
Sánchez Tijmes F, Marschner C, de Matos J, Urzua Fresno C, Gutiérrez Chacoff J, Thavendiranathan P, Fuss C, Hanneman K. Imaging Acute and Chronic Cardiac Complications of COVID-19 and after COVID-19 Vaccination. RadioGraphics 2023, 43: e230044. PMID: 37616171, DOI: 10.1148/rg.230044.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementGadolinium enhancementCardiac MRICOVID-19 vaccinePattern of late gadolinium enhancementCardiac complications of COVID-19MRNA-based COVID-19 vaccinesPresence of cardiovascular diseaseStress-induced cardiomyopathyMultimodality cardiac imagingBasal inferolateral wallMinority of patientsPersistent cardiac symptomsAdverse cardiovascular eventsComplications of COVID-19Chronic cardiac complicationsManifestations of COVID-19Potential mechanisms of injuryMechanism of injuryCardiovascular manifestations of COVID-19Messenger ribonucleic acidAcute COVID-19Cardiac symptomsCardiovascular manifestationsImaging findingsCytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
Barmada A, Klein J, Ramaswamy A, Brodsky N, Jaycox J, Sheikha H, Jones K, Habet V, Campbell M, Sumida T, Kontorovich A, Bogunovic D, Oliveira C, Steele J, Hall E, Pena-Hernandez M, Monteiro V, Lucas C, Ring A, Omer S, Iwasaki A, Yildirim I, Lucas C. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Science Immunology 2023, 8: eadh3455-eadh3455. PMID: 37146127, PMCID: PMC10468758, DOI: 10.1126/sciimmunol.adh3455.Peer-Reviewed Original ResearchConceptsMRNA vaccinesSARS-CoV-2 mRNA vaccinesSARS-CoV-2 mRNA vaccinationC-reactive protein levelsB-type natriuretic peptidePeripheral blood mononuclear cellsCardiac tissue inflammationDeep immune profilingSerum soluble CD163Vaccine-associated myocarditisCohort of patientsBlood mononuclear cellsCytotoxic T cellsLate gadolinium enhancementHypersensitivity myocarditisElevated troponinMRNA vaccinationImaging abnormalitiesNK cellsImmune profilingKiller cellsMyeloid responseNatriuretic peptideHumoral mechanismsInflammatory cytokinesImpaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis
Feher A, Miller E, Peters D, Mojibian H, Sinusas A, Hinchcliff M, Baldassarre L. Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis. Rheumatology International 2023, 43: 849-858. PMID: 36894756, DOI: 10.1007/s00296-023-05294-6.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementLV-GLSSystemic sclerosisWorse survivalClinical indicationsImpaired left ventricular global longitudinal strainLeft ventricular global longitudinal strainPresence of LGECMR strainLV cardiac indexWorse LV-GLSLV ejection fractionCox regression analysisGlobal longitudinal strainLV cardiac outputGlobal radialCardiac indexOverall survivalRetrospective cohortEjection fractionPrognostic valueAdverse outcomesCardiac outputGadolinium enhancementRV strain
2022
Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis
Dohy Z, Szabo L, Pozsonyi Z, Csecs I, Toth A, Suhai F, Czimbalmos C, Szucs A, Kiss A, Becker D, Merkely B, Vago H. Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis. PLOS ONE 2022, 17: e0269807. PMID: 35696411, PMCID: PMC9191721, DOI: 10.1371/journal.pone.0269807.Peer-Reviewed Original ResearchConceptsCardiac AL amyloidosisCardiac magnetic resonanceLate gadolinium enhancementAL amyloidosisOptimal diagnostic performanceHypertrophic cardiomyopathyDegree of left ventricular (LV) hypertrophyReduced global LV longitudinal strainDiagnostic performanceLeft ventricular (LV) hypertrophyPattern of late gadolinium enhancementGlobal LV longitudinal strainSubendocardial late gadolinium enhancementCardiac magnetic resonance examinationCardiac magnetic resonance parametersCardiac light-chain amyloidosisDifferential diagnosis of cardiomyopathyLV strain parametersCardiac transthyretin amyloidosisLV) hypertrophyLV longitudinal strainDiagnosis of cardiomyopathyLight chain amyloidosisCardiac light chainsPotential clinical relevance
2021
COVID-19 Vaccination–Associated Myocarditis in Adolescents
Jain SS, Steele JM, Fonseca B, Huang S, Shah S, Maskatia SA, Buddhe S, Misra N, Ramachandran P, Gaur L, Eshtehardi P, Anwar S, Kaushik N, Han F, Chaudhuri NR, Grosse-Wortmann L. COVID-19 Vaccination–Associated Myocarditis in Adolescents. Pediatrics 2021, 148: e2021053427. PMID: 34389692, DOI: 10.1542/peds.2021-053427.Peer-Reviewed Original ResearchConceptsCardiovascular magnetic resonanceMultisystem inflammatory syndromeMyocardial tissue changesInflammatory syndromeVentricular dysfunctionMyocardial injuryTissue changesExcellent short-term outcomesMild left ventricular dysfunctionDifferent pediatric age groupsQuick clinical recoveryLeft ventricular dysfunctionResolution of symptomsRetrospective multicenter studyPediatric age groupShort-term outcomesShort-term prognosisMessenger RNA vaccinesLate gadolinium enhancementYears of ageLake Louise criteriaSignificant dysrhythmiasHospital courseClinical characteristicsClinical recoveryLeft atrial evaluation by cardiovascular magnetic resonance: sensitive and unique biomarkers
Peters DC, Lamy J, Sinusas AJ, Baldassarre LA. Left atrial evaluation by cardiovascular magnetic resonance: sensitive and unique biomarkers. European Heart Journal - Cardiovascular Imaging 2021, 23: 14-30. PMID: 34718484, PMCID: PMC8685602, DOI: 10.1093/ehjci/jeab221.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementAtrial fibrillationCardiovascular magnetic resonanceDiastolic dysfunctionEjection fractionAF recurrenceAtrial fibrosisNew-onset atrial fibrillationPost-operative atrial fibrillationLongitudinal LA strainExtent of fibrosisLong-axis cine imagesCine imagesAtrial imagingCardiovascular eventsLA volumeRisk stratificationAF subjectsPrognostic informationHypertrophic cardiomyopathyLA strainGadolinium enhancementSensitive markerAblation proceduresMagnetic resonanceThe role of feature-tracking strain analysis in the differentiation of cardiac amyloidosis from hypertrophic cardiomyopathy
Dohy Z, Szabo L, Pozsonyi Z, Csecs I, Toth A, Suhai F, Czimbalmos C, Szucs A, Kiss A, Becker D, Merkely B, Vago H. The role of feature-tracking strain analysis in the differentiation of cardiac amyloidosis from hypertrophic cardiomyopathy. European Heart Journal 2021, 42: ehab724.0240. DOI: 10.1093/eurheartj/ehab724.0240.Peer-Reviewed Original ResearchCardiac involvement of amyloidosisLeft ventricular ejection fractionLate gadolinium enhancementCardiac magnetic resonanceAmount of late gadolinium enhancementHypertrophic cardiomyopathy patientsFeature-tracking strain analysisCA patientsHypertrophic cardiomyopathyBasal LSDiagnostic accuracyPattern of late gadolinium enhancementCardiac magnetic resonance diagnosisCardiac magnetic resonance examinationSignificant independent predictors of mortalityCox proportional hazards regression analysisIndependent predictor of mortalityLV strain parametersRegional strain valuesYears of follow-upProportional hazards regression analysisVentricular ejection fractionOptimal cutoff valueLog-rank testDiagnosis of CAMachine learning phenotyping of scarred myocardium from cine in hypertrophic cardiomyopathy
Mancio J, Pashakhanloo F, El-Rewaidy H, Jang J, Joshi G, Csecs I, Ngo L, Rowin E, Manning W, Maron M, Nezafat R. Machine learning phenotyping of scarred myocardium from cine in hypertrophic cardiomyopathy. European Heart Journal - Cardiovascular Imaging 2021, 23: 532-542. PMID: 33779725, PMCID: PMC9125682, DOI: 10.1093/ehjci/jeab056.Peer-Reviewed Original ResearchLeft ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity
Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLOS ONE 2021, 16: e0246764. PMID: 33606757, PMCID: PMC7895343, DOI: 10.1371/journal.pone.0246764.Peer-Reviewed Original ResearchConceptsGlobal longitudinal strainImmune checkpoint inhibitorsLate gadolinium enhancementRecovery of LVEFLake Louise criteriaCheckpoint inhibitorsNormal LVEFAverage global longitudinal strainPresence of LGEAbnormal global longitudinal strainCardiac magnetic resonance imagingCorrect clinical contextEvaluation of myocarditisLeft ventricular dysfunctionVentricular ejection fractionDiagnosis of myocarditisLeft ventricular strainCardiac magnetic resonanceLeft ventricular myocardial strainOvert left ventricular dysfunctionVentricular myocardial strainMagnetic resonance imagingAtrial strainVentricular dysfunctionVentricular strain
2020
Left atrial late gadolinium enhancement is associated with atrial fibrillation as detected by continuous monitoring
Bertelsen L, Diederichsen S, Haugan K, Brandes A, Graff C, Krieger D, Kronborg C, Kober L, Peters D, Olesen M, Hojberg S, Vejlstrup N, Svendsen J. Left atrial late gadolinium enhancement is associated with atrial fibrillation as detected by continuous monitoring. European Heart Journal 2020, 41: ehaa946.0308. DOI: 10.1093/ehjci/ehaa946.0308.Peer-Reviewed Original ResearchImplantable loop recorderIncident AFAtrial late gadolinium enhancementLA-LGELate gadolinium enhancementLoop recorderLA volumeLeft ventricularAF episodesGadolinium enhancementLV extracellular volume fractionCardiac magnetic resonance imagingAF ablation proceduresCox regression analysisMultivariable risk prediction modelMagnetic resonance imagingRisk prediction modelExtracellular volume fractionUnknown AFLA fibrosisHazard ratioAtrial fibrillationPrognostic valueAtrial fibrosisRisk factorsDifferentiation between physiological sport adaptation and hypertrophic cardiomyopathy in highly trained athletes using cardiac magnetic resonance
Czimbalmos C, Nardocci C, Deetjen E, Szabo L, Dohy Z, Toth A, Suhai F, Csecs I, Horvath V, Kiss O, Sydo N, Merkely B, Vago H. Differentiation between physiological sport adaptation and hypertrophic cardiomyopathy in highly trained athletes using cardiac magnetic resonance. European Heart Journal 2020, 41: ehaa946.3119. DOI: 10.1093/ehjci/ehaa946.3119.Peer-Reviewed Original ResearchCardiac magnetic resonance parametersCardiac magnetic resonanceLate gadolinium enhancementDiagnosis of hypertrophic cardiomyopathyHypertrophic cardiomyopathyCut-off valueHCM patientsHealthy athletesPresence of late gadolinium enhancementOptimal cut-off valueCardiac magnetic resonance characteristicsConventional CMR parametersReceiver operating curve analysisDiagnose HCMEnd-diastolic wall thicknessPathological left ventricular hypertrophyOperating curve analysisGlobal longitudinalGadolinium enhancementLV functionVentricular hypertrophyCMR parametersClinical conundrumHypertrophy patternCurve analysisAssociation Between Left Ventricular Mechanical Deformation and Myocardial Fibrosis in Nonischemic Cardiomyopathy
Csecs I, Pashakhanloo F, Paskavitz A, Jang J, Al‐Otaibi T, Neisius U, Manning W, Nezafat R. Association Between Left Ventricular Mechanical Deformation and Myocardial Fibrosis in Nonischemic Cardiomyopathy. Journal Of The American Heart Association 2020, 9: e016797. PMID: 33006296, PMCID: PMC7792406, DOI: 10.1161/jaha.120.016797.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementSeptal late gadolinium enhancementLV ejection fractionNonischemic cardiomyopathyExtent of fibrosisCardiovascular magnetic resonanceEjection fractionImpaired global circumferential strainImpaired LV ejection fractionLate gadolinium enhancement groupsDepressed LV ejection fractionClinical cardiovascular magnetic resonanceLeft ventricular (LVLGE-negative groupCircumferential strainGlobal radial strainGlobal longitudinal strainRadial strainGlobal circumferential strainLV deformation parametersGlobal LV functionAdverse cardiovascular outcomesLGE-positiveNonischemic fibrosisFibrosis burdenDesmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy
Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, Agarwal PP, Arscott P, Dellefave-Castillo LM, Vorovich EE, Nutakki K, Wilsbacher LD, Priori SG, Jacoby DL, McNally EM, Helms AS. Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation 2020, 141: 1872-1884. PMID: 32372669, PMCID: PMC7286080, DOI: 10.1161/circulationaha.119.044934.Peer-Reviewed Original ResearchConceptsLV late gadolinium enhancementLate gadolinium enhancementSevere ventricular arrhythmiasAcute myocardial injuryMyocardial injuryRight ventricular cardiomyopathyVentricular arrhythmiasGadolinium enhancementVentricular cardiomyopathyEjection fractionSevere arrhythmiasFrequent premature ventricular contractionsPathogenic plakophilin-2 mutationNormal LV systolic functionLeft ventricle ejection fractionRight ventricular ejection fractionPositron emission tomography scanArrhythmogenic right ventricular cardiomyopathyNormal ventricular functionLV systolic functionVentricle ejection fractionVentricular ejection fractionEmission tomography scanSmall case seriesPlakophilin-2 mutationsP363 Cardiac magnetic resonance characteristics of patients in the grey zone of hypertrophy
Czimbalmos C, Csecs I, Horvath V, Deetjen E, Nardocci C, Dohy Z, Szabo L, Suhai F, Toth A, Sydo N, Kiss O, Merkely B, Vago H. P363 Cardiac magnetic resonance characteristics of patients in the grey zone of hypertrophy. European Heart Journal - Cardiovascular Imaging 2020, 21 DOI: 10.1093/ehjci/jez319.212.Peer-Reviewed Original ResearchLate gadolinium enhancementCardiac magnetic resonancePresence of late gadolinium enhancementHCM patientsHypertrophic cardiomyopathyInter-observer analysisHealthy athletesGadolinium enhancementCardiac magnetic resonance characteristicsStandard deviation of timeConventional CMR parametersMale HCM patientsEnd-diastolic wall thicknessGlobal strain valuesCut-off valueCharacteristics of patientsGray zoneGlobal longitudinalIntraventricular dyssynchronyHypertrophic segmentsCMR parametersDifferential diagnosisDelayed contrastHCM groupPatient group
2019
Baseline Characteristics of the VANISH Cohort
Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY. Baseline Characteristics of the VANISH Cohort. Circulation Heart Failure 2019, 12: e006231. PMID: 31813281, PMCID: PMC7219518, DOI: 10.1161/circheartfailure.119.006231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAngiotensin II Type 1 Receptor BlockersBrazilCanadaCardiomyopathy, HypertrophicChildDenmarkDisease ProgressionDouble-Blind MethodFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationPhenotypeRecovery of FunctionSarcomeresTime FactorsTreatment OutcomeUnited StatesValsartanYoung AdultConceptsAngiotensin receptor blockersHypertrophic cardiomyopathyReceptor blockersBaseline characteristicsImaging abnormalitiesPrimary cohortMutation carriersNew York Heart Association class IINew York Heart Association classFunctional class II symptomsOlder ageClass II symptomsNonobstructive hypertrophic cardiomyopathyNormal functional capacityPrevious trialsVentricular wall thicknessPeak oxygen consumptionPlacebo-controlled designCardiac magnetic resonanceGene mutation carriersLate gadolinium enhancementVANISH trialAdvanced diseaseAssociation classVentricular hypertrophy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply